Category survey

The development and testing of a communication skills training intervention for healthcare professionals caring for people with dementia in acute hospitals

The development and testing of a communication skills training intervention for healthcare professionals caring for people with dementia in acute hospitals Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

A multi-site evaluation of the Person, Interactions & Environment (PIE) tool to improve person-centred care for people with dementia admitted to acute hospital wards

A multi-site evaluation of the Person, Interactions & Environment (PIE) tool to improve person-centred care for people with dementia admitted to acute hospital wards Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

MemoryCare: Investigating the management of refusal of care in people with dementia admitted to hospital with an acute condition

MemoryCare: Investigating the management of refusal of care in people with dementia admitted to hospital with an acute condition Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Embedding a Human Rights Based Approach to Dementia Care

Embedding a Human Rights Based Approach to Dementia Care Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

DREAMS (Dementia Related Manual for Sleep) START (Strategies for Relatives)

DREAMS (Dementia Related Manual for Sleep) START (Strategies for Relatives) Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: A realist review and feasibility study for a cluster randomised controlled trial

The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: A realist review and feasibility study for a cluster randomised controlled trial Investments > €500k United Kingdom Alzheimer’s disease & other…

Optimising acute care for people with dementia: a mixed-methods study

Optimising acute care for people with dementia: a mixed-methods study Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

A Multicentre Biomarker Resource Strategy in ALS: AMBRoSIA

A Multicentre Biomarker Resource Strategy in ALS: AMBRoSIA Investments > €500k United Kingdom Motor neurone diseases 2016

NECTAR – Genetic Screening Component of AMBRoSIA (Biomarkers Study)

NECTAR – Genetic Screening Component of AMBRoSIA (Biomarkers Study) Investments > €500k United Kingdom Motor neurone diseases 2016

A trial to assess the safety and efficacy of intermittent putamenal GDNF infusions administered via Convection Enhanced Delivery (CED) in Parkinson’s

A trial to assess the safety and efficacy of intermittent putamenal GDNF infusions administered via Convection Enhanced Delivery (CED) in Parkinson’s Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Generation of induced pluripotent stem cells from people with Parkinson’s / Modelling Parkinson’s with rat embryonic stem cells and transgenesis (extension)

Generation of induced pluripotent stem cells from people with Parkinson’s / Modelling Parkinson’s with rat embryonic stem cells and transgenesis (extension) Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Tracking Parkinson’s: Parkinson’s repository of biomarkers and networked datasets (PROBAND)

Tracking Parkinson’s: Parkinson’s repository of biomarkers and networked datasets (PROBAND) Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

PaMIR: Parkinson MR imaging repository

PaMIR: Parkinson MR imaging repository Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Understanding the pathological pathways to Parkinson’s

Understanding the pathological pathways to Parkinson’s Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Tracking Parkinson’s with proteomic biomarkers

Tracking Parkinson’s with proteomic biomarkers Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Targeting the pathological pathways to Parkinson’s

Targeting the pathological pathways to Parkinson’s Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

The molecular mechanisms of structural conversion and toxicity in amyloid disease.

The molecular mechanisms of structural conversion and toxicity in amyloid disease. Investments > €500k United Kingdom Neurodegenerative disease in general 2016

A Systematic Programme to Develop and Evaluate the Best Candidate Treatments for Repositioning as Therapies for Alzheimer s Disease (SMART-AD).

A Systematic Programme to Develop and Evaluate the Best Candidate Treatments for Repositioning as Therapies for Alzheimer s Disease (SMART-AD). Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Apolipoprotein E4 as a Therapeutic Target for Alzheimer’s Disease: Identification of Small-Molecule Structure Correctors That Prevent Apolipoprotein E4 Associated Neuropathology

Apolipoprotein E4 as a Therapeutic Target for Alzheimer’s Disease: Identification of Small-Molecule Structure Correctors That Prevent Apolipoprotein E4 Associated Neuropathology Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Design and Optimisation of New Chemical Entities that Prevent the Neurotoxic Oligomerization and Misfolding of both beta-amyloid and tau Proteins: A Disease Modifying Therapeutics Approach for Alzheimer’s Dementia

Design and Optimisation of New Chemical Entities that Prevent the Neurotoxic Oligomerization and Misfolding of both beta-amyloid and tau Proteins: A Disease Modifying Therapeutics Approach for Alzheimer’s Dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016 …

Administration of VEGF (sNN0029) using an implanted drug delivery system for adose escalation study in patients with Amyotrophic Lateral Sclerosis.

Administration of VEGF (sNN0029) using an implanted drug delivery system for adose escalation study in patients with Amyotrophic Lateral Sclerosis. Investments > €500k United Kingdom Motor neurone diseases 2016

Molecular Basis of Protein Misfolding Disorders.

Molecular Basis of Protein Misfolding Disorders. Investments > €500k United Kingdom Neurodegenerative disease in general 2016

Consortium of Neuroimmunology of Mood Disorders and Alzheimer’s Disease.

Consortium of Neuroimmunology of Mood Disorders and Alzheimer’s Disease. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Mechanisms of neurotoxicity of amyloid aggregates.

Mechanisms of neurotoxicity of amyloid aggregates. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson’s disease (PD MED)

A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson’s disease (PD MED) Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Evaluating the effectiveness and cost effectiveness of Dementia Care Mapping (DCM) to enable person-centred Care for people with dementia and their carers: A UK cluster randomised controlled trial in care homes (DCM EPIC trial)

Evaluating the effectiveness and cost effectiveness of Dementia Care Mapping (DCM) to enable person-centred Care for people with dementia and their carers: A UK cluster randomised controlled trial in care homes (DCM EPIC trial) Investments > €500k United Kingdom Alzheimer’s…

A multi-centre randomised controlled trial of Comprehensive Geriatric Assessment in an admission avoidance hospital at home setting

A multi-centre randomised controlled trial of Comprehensive Geriatric Assessment in an admission avoidance hospital at home setting Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Living well with dementia

Living well with dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Inciting dialogue and disruption – developing participatory analysis of the experience of living with dementia and dementia care

Inciting dialogue and disruption – developing participatory analysis of the experience of living with dementia and dementia care Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

The MARQUE project: Managing Agitation and Raising QUality of Life. A project to improve quality of life in people with moderate or severe dementia

The MARQUE project: Managing Agitation and Raising QUality of Life. A project to improve quality of life in people with moderate or severe dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Dementia-friendly architecture: Reducing Spatial Disorientation in Dementia Care Homes

Dementia-friendly architecture: Reducing Spatial Disorientation in Dementia Care Homes Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Seeing what they see: compensating for cortical visual dysfunction in Alzheimer’s disease

Seeing what they see: compensating for cortical visual dysfunction in Alzheimer’s disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Neighbourhoods and Dementia: A mixed methods study

Neighbourhoods and Dementia: A mixed methods study Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Comprehensive approach to modelling outcome and cost impacts of interventions for dementia

Comprehensive approach to modelling outcome and cost impacts of interventions for dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

PRIDE – Promoting Independence in Dementia

PRIDE – Promoting Independence in Dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Maintaining function and well-being in later life: A longitudinal cohort study

Maintaining function and well-being in later life: A longitudinal cohort study Investments > €500k United Kingdom Neurodegenerative disease in general 2016

Technology enriched supported housing a study into the lived experience of older people with dementia and their carers

Technology enriched supported housing a study into the lived experience of older people with dementia and their carers Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Quantification of vascular disease burden to stratify dementia for diagnosis and care managemnt

Quantification of vascular disease burden to stratify dementia for diagnosis and care managemnt Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

Development of prognostic epigenetic biomarkers for ALS

Development of prognostic epigenetic biomarkers for ALS Investments > €500k United Kingdom Motor neurone diseases 2016

mTOR signalling pathway in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI).

mTOR signalling pathway in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI). Investments > €500k United Kingdom Neurodegenerative disease in general 2016

A Digital Brain Health Platform for improving dementia outcomes

A Digital Brain Health Platform for improving dementia outcomes Investments > €500k United Kingdom Neurodegenerative disease in general 2016

CloudUPDRS: Big Data Analytics for Parkinson’s Disease patient stratification

CloudUPDRS: Big Data Analytics for Parkinson’s Disease patient stratification Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016

Extraction and modelling of Alzheimer’s disease data for patient stratification: integrative, multiplex network approach

Extraction and modelling of Alzheimer’s disease data for patient stratification: integrative, multiplex network approach Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016

The UK National Motor Neurone Disease Registry

The UK National Motor Neurone Disease Registry Investments > €500k United Kingdom Motor neurone diseases 2016

Generation and characterisation of induced pluripotent stem cells from ALS lymphoblasts to model disease pathogenesis and advanced drug discovery

Generation and characterisation of induced pluripotent stem cells from ALS lymphoblasts to model disease pathogenesis and advanced drug discovery Investments > €500k United Kingdom Motor neurone diseases 2016